Absci Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABSI research report →
Companywww.absci.com
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
- CEO
- Sean McClain
- IPO
- 2021
- Employees
- 156
- HQ
- Vancouver, WA, US
Price Chart
Valuation
- Market Cap
- $771.73M
- P/E
- -6.39
- P/S
- 420.33
- P/B
- 4.40
- EV/EBITDA
- -6.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1316.88%
- Op Margin
- -7000.82%
- Net Margin
- -6450.76%
- ROE
- -63.58%
- ROIC
- -72.28%
Growth & Income
- Revenue
- $2.80M · -38.24%
- Net Income
- $-115,183,000 · -11.71%
- EPS
- $-0.84 · 10.64%
- Op Income
- $-124,718,000
- FCF YoY
- -29.15%
Performance & Tape
- 52W High
- $6.72
- 52W Low
- $2.24
- 50D MA
- $3.82
- 200D MA
- $3.33
- Beta
- 2.38
- Avg Volume
- 5.16M
Get TickerSpark's AI analysis on ABSI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Pangalos Menelas N | buy | 37,453 |
| Mar 12, 26 | Busch Andreas | buy | 100,000 |
| Mar 2, 26 | Pangalos Menelas N | other | 5,800 |
| Mar 2, 26 | Pangalos Menelas N | other | 22,800 |
| Mar 2, 26 | Walker Shelby J. | other | 356,300 |
| Mar 2, 26 | Walker Shelby J. | other | 90,300 |
| Mar 3, 26 | Walker Shelby J. | other | 9,825 |
| Mar 2, 26 | McClain Sean | other | 406,200 |
| Mar 3, 26 | McClain Sean | other | 25,316 |
| Mar 2, 26 | McClain Sean | other | 1,603,200 |
Our ABSI Coverage
We haven't published any research on ABSI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABSI Report →